Cargando…

Clinical evaluation of serum tumour marker CA 242 in non-small cell lung cancer.

CA 242, a novel tumour carbohydrate antigen present in serum (upper limit of normal values: 20.0 U ml-1), has been measured in a group of 102 pathologically confirmed non-small cell lung cancer patients. The aim of the present prospective study was to identify any relationship between pre-treatment...

Descripción completa

Detalles Bibliográficos
Autores principales: Pujol, J. L., Cooper, E. H., Lehmann, M., Purves, D. A., Dan-Aouta, M., Midander, J., Godard, P., Michel, F. B.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1993
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1968478/
https://www.ncbi.nlm.nih.gov/pubmed/8390291
_version_ 1782134749085564928
author Pujol, J. L.
Cooper, E. H.
Lehmann, M.
Purves, D. A.
Dan-Aouta, M.
Midander, J.
Godard, P.
Michel, F. B.
author_facet Pujol, J. L.
Cooper, E. H.
Lehmann, M.
Purves, D. A.
Dan-Aouta, M.
Midander, J.
Godard, P.
Michel, F. B.
author_sort Pujol, J. L.
collection PubMed
description CA 242, a novel tumour carbohydrate antigen present in serum (upper limit of normal values: 20.0 U ml-1), has been measured in a group of 102 pathologically confirmed non-small cell lung cancer patients. The aim of the present prospective study was to identify any relationship between pre-treatment serum CA 242 level and different features of lung cancer including prognosis. Serum CA 242 was measured using the delayed europium lanthanide fluoroimmunometric assay. Sensitivity and specificity were 28.5% and 95.6% respectively. Its level was significantly lower in squamous cell carcinoma in comparison with non-squamous histologies (adenocarcinoma and large cell carcinoma). The CA 242 level was higher in metastatic disease (median: 15.3 U ml-1) in comparison with non-metastatic (median: 7.9 U ml-1; Mann Whitney U test; P < 0.003), and increased significantly from stage I to stage IV. In 50 patients who underwent chemotherapy, the serum CA 242 level was higher in non-responder patients when compared with responders (median: 16.8 U ml-1 and 9.5 U ml-1 respectively; Mann Whitney; P < 0.02). Univariate analysis of the entire population showed serum CA 242 levels were not related to survival. However, patients with unresectable non-small cell lung cancer and elevated CA 242 level proved to have a significantly shorter survival than those with a CA 242 < 20 U ml-1. In Cox's model analysis, stage of the disease and performance status were the only significant determinants of survival. We conclude that a high level of serum CA 242 (1) is significantly related to the stage of disease, (2) predictive of no response to chemotherapy but seems to add weak prognostic information to stage of disease and performance status, the main prognostic determinants of non-small cell lung cancer.
format Text
id pubmed-1968478
institution National Center for Biotechnology Information
language English
publishDate 1993
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-19684782009-09-10 Clinical evaluation of serum tumour marker CA 242 in non-small cell lung cancer. Pujol, J. L. Cooper, E. H. Lehmann, M. Purves, D. A. Dan-Aouta, M. Midander, J. Godard, P. Michel, F. B. Br J Cancer Research Article CA 242, a novel tumour carbohydrate antigen present in serum (upper limit of normal values: 20.0 U ml-1), has been measured in a group of 102 pathologically confirmed non-small cell lung cancer patients. The aim of the present prospective study was to identify any relationship between pre-treatment serum CA 242 level and different features of lung cancer including prognosis. Serum CA 242 was measured using the delayed europium lanthanide fluoroimmunometric assay. Sensitivity and specificity were 28.5% and 95.6% respectively. Its level was significantly lower in squamous cell carcinoma in comparison with non-squamous histologies (adenocarcinoma and large cell carcinoma). The CA 242 level was higher in metastatic disease (median: 15.3 U ml-1) in comparison with non-metastatic (median: 7.9 U ml-1; Mann Whitney U test; P < 0.003), and increased significantly from stage I to stage IV. In 50 patients who underwent chemotherapy, the serum CA 242 level was higher in non-responder patients when compared with responders (median: 16.8 U ml-1 and 9.5 U ml-1 respectively; Mann Whitney; P < 0.02). Univariate analysis of the entire population showed serum CA 242 levels were not related to survival. However, patients with unresectable non-small cell lung cancer and elevated CA 242 level proved to have a significantly shorter survival than those with a CA 242 < 20 U ml-1. In Cox's model analysis, stage of the disease and performance status were the only significant determinants of survival. We conclude that a high level of serum CA 242 (1) is significantly related to the stage of disease, (2) predictive of no response to chemotherapy but seems to add weak prognostic information to stage of disease and performance status, the main prognostic determinants of non-small cell lung cancer. Nature Publishing Group 1993-06 /pmc/articles/PMC1968478/ /pubmed/8390291 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Research Article
Pujol, J. L.
Cooper, E. H.
Lehmann, M.
Purves, D. A.
Dan-Aouta, M.
Midander, J.
Godard, P.
Michel, F. B.
Clinical evaluation of serum tumour marker CA 242 in non-small cell lung cancer.
title Clinical evaluation of serum tumour marker CA 242 in non-small cell lung cancer.
title_full Clinical evaluation of serum tumour marker CA 242 in non-small cell lung cancer.
title_fullStr Clinical evaluation of serum tumour marker CA 242 in non-small cell lung cancer.
title_full_unstemmed Clinical evaluation of serum tumour marker CA 242 in non-small cell lung cancer.
title_short Clinical evaluation of serum tumour marker CA 242 in non-small cell lung cancer.
title_sort clinical evaluation of serum tumour marker ca 242 in non-small cell lung cancer.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1968478/
https://www.ncbi.nlm.nih.gov/pubmed/8390291
work_keys_str_mv AT pujoljl clinicalevaluationofserumtumourmarkerca242innonsmallcelllungcancer
AT coopereh clinicalevaluationofserumtumourmarkerca242innonsmallcelllungcancer
AT lehmannm clinicalevaluationofserumtumourmarkerca242innonsmallcelllungcancer
AT purvesda clinicalevaluationofserumtumourmarkerca242innonsmallcelllungcancer
AT danaoutam clinicalevaluationofserumtumourmarkerca242innonsmallcelllungcancer
AT midanderj clinicalevaluationofserumtumourmarkerca242innonsmallcelllungcancer
AT godardp clinicalevaluationofserumtumourmarkerca242innonsmallcelllungcancer
AT michelfb clinicalevaluationofserumtumourmarkerca242innonsmallcelllungcancer